切换至 "中华医学电子期刊资源库"

中华消化病与影像杂志(电子版) ›› 2018, Vol. 08 ›› Issue (04) : 163 -165. doi: 10.3877/cma.j.issn.2095-2015.2018.04.005

所属专题: 文献

综述

非酒精性脂肪性肝病与肠道菌群的关系
王冰心1, 白珊珊1, 张佳佳1, 党小红2,()   
  1. 1. 030000 太原,山西医科大学在读硕士研究生
    2. 030000 太原,山西医科大学第一医院消化内科
  • 收稿日期:2018-04-12 出版日期:2018-08-01
  • 通信作者: 党小红

Relationship between non-alcoholic fatty liver disease and intestinal flora

Bingxin Wang1, Shanshan Bai1, Jiajia Zhang1, Xiaohong Dang2,()   

  1. 1. Postgraduate Student, Shanxi Medical University
    2. Department of Gastroenterology, First Hospital of Shanxi Medical University, Taiyuan 030000, China
  • Received:2018-04-12 Published:2018-08-01
  • Corresponding author: Xiaohong Dang
  • About author:
    Corresponding author: Dang Xiaohong, Email:
引用本文:

王冰心, 白珊珊, 张佳佳, 党小红. 非酒精性脂肪性肝病与肠道菌群的关系[J/OL]. 中华消化病与影像杂志(电子版), 2018, 08(04): 163-165.

Bingxin Wang, Shanshan Bai, Jiajia Zhang, Xiaohong Dang. Relationship between non-alcoholic fatty liver disease and intestinal flora[J/OL]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2018, 08(04): 163-165.

非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是一种多病因导致的临床病理综合征,已成为最常见的慢性肝病之一,目前NAFLD完整的生理机制尚不完全清楚,近年来提出肠道菌群通过调控能量代谢、增加内源性乙醇、调节胆汁酸及胆碱代谢,破坏免疫平衡引发机体低度炎症等途径促进NAFLD的发生、发展,本文就肠道菌群与NAFLD的相关机制做一概述。

Non-alcoholic fatty liver disease(NAFLD)is a clinical pathological syndrome caused by multiple etiologies.It has become one of the most common chronic liver diseases.The complete physiological mechanism of NAFLD is not fully understood.The recent researches suggest that intestinal flora can promote the occurrence and development of NAFLD by regulating the energy metabolism, increasing the endogenous ethanol, adjusting metabolism of bile acid and choline, damaging the immune balance and triggering the low-grade inflammation.This paper summarizes the mechanism of intestinal flora and NAFLD.

14
Aron-Wisnewsky J, Gaborit B, Dutour A, et al.Gut microbiota and non-alcoholic fatty liver disease: new insights[J]. Clin Microbiol Infect, 2013, 19(4): 338-348.
15
Zhu LX, Baker SS, Gill C, et al.Characterization of gut microbiomes in nonalcoholic steatohepatitis(NASH)patients: a connection between endogenous alcohol and NASH[J]. Hepatology, 2013, 57(2): 601-609.
16
申瑞玲,林娟.肠道菌群与Ⅱ型糖尿病作用机制综述[J].粮食与油脂, 2014, 27(9): 5-8.
17
Spencer MD, Hamp TJ, Reid RW, et al.Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency[J]. Gastroenterology, 2011, 140(3): 976-986.
18
欧强,杨华,赵亚娟,吴晓林.蛋氨酸-胆碱缺乏饮食诱导的大、小鼠非酒精性脂肪性肝病模型的特点及差异[J].肝脏, 2017, 22(10): 933-937.
19
Sherriff JL, O′Sullivan TA, et al.Choline, Its Potential Role in Nonalcoholic Fatty Liver Disease, and the Case for Human and Bacterial Genes[J]. Adv Nutr, 2016, 7(1): 5-13.
20
张久聪,聂青和.胆汁酸代谢及相关进展[J].胃肠病学和肝病学杂志, 2008(11): 953-956.
21
McMahan R, Wang XX, Cheng LL, et al.Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease[J]. J Biol Chem, 2013, 288(7): 11761-11770.
22
Schubert K, Olde Damink Steven WM, von BM, et al.Interactions between bile salts, gut microbiota, and hepatic innate immunity[J]. Immunol Rev, 2017, 279(1): 23-35.
23
Takeuchi O, Akira SZ.Pattern recognition receptors and inflammation[J]. Cell, 2010, 140(6): 805-820.
24
Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20(23): 7381-7391.
25
殷小磊,卢伟娜,冯丽英.LPS/TLR4信号途径在非酒精性脂肪性肝病中的作用[J].世界华人消化杂志, 2013, 21(28): 2957-2962.
26
Cani PD, Amar J, Iglesias MA, et al.Metabolic endotoxemia initiates obesity and insulin resistance[J]. Diabetes, 2007, 56(7): 1761-1772.
27
Miura K, Kodama Y, Inokuchi S, et al.Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice[J]. Gastroenterology, 2010, 139(1): 323-334.e7.
28
Pekkala S, Munukka E, Kong LJ, et al.Toll-like receptor 5 in obesity: the role of gut microbiota and adipose tissue inflammation[J]. Obesity(Silver Spring), 2015, 23(3): 581-590.
1
Buzzetti E, Pinzani M, Tsochatzis EA.The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)[J]. Metabolism, 2016, 65(8): 1038-1048.
2
Zezos P, Renner EL.Liver transplantation and non-alcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20(42): 15532-15538.
3
Bedossa P. Pathology of non-alcoholic fatty liver disease[J]. Liver Int, 2017, 37(suppl 1): 85-89.
4
Roberfroid M, Gibson GR, Hoyles L, et al.Prebiotic effects: Metabolic and health benefits[J]. Br J Nutr, 2010, 104(suppl 2): s1-s63.
5
Robles AV, Guarner F. Linking the gut microbiota to human health[J]. Br J Nutr, 2013, 109, (suppl 2): S21-S26.
6
Le CE, Nielsen T, Qin JJ.Richness of human gut microbiome correlates with metabolic markers[J]. Nature, 2013, 500(7464): 541-546.
7
刘慧,朱文娅,孙涛.非酒精性脂肪性肝病肠道菌群变化及其与胰岛素抵抗的关系[J].中国临床医生, 2014, 42(5): 31-33.
8
丁佳,吴健.肠-肝轴与非酒精性脂肪性肝病[J].微生物与感染, 2014, 9(2): 65-70.
9
王峻瑶,刘玉兰.肠-肝轴在非酒精性脂肪性肝病发生和发展中的作用[J].实用肝脏病杂志, 2012, 15(4): 276-278.
10
Wieland A, Frank DN, Harnke B, et al.Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2015, 42(9): 1051-1063.
11
Poeta M, Pierri L, Vajro P. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease[J]. Children(Basel), 2017, 4(8). pii: E66.
12
Bäckhed F, Ding H, Wang T, et al.The gut microbiota as an environmental factor that regulates fat storage[J]. Proc Natl Acad Sci U S A, 2004, 101(44): 15718-15723.
13
Samuel BS, Shaito A, Motoike T, et al.Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41[J]. Proc Natl Acad Sci U S A, 2008, 105(43): 16767-16772.?
29
Wree A, McGeough MD, Inzaugarat ME, et al.NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF[J]. Hepatology, 2017.
30
Levy M, Shapiro H, Thaiss CA, et al.NLRP6: A Multifaceted Innate Immune Sensor[J]. Trends Immunol, 2017, 38(4): 248-260.
[1] 郝玥萦, 毛盈譞, 张羽, 汪佳旭, 韩林霖, 匡雯雯, 孟瑶, 杨秀华. 超声引导衰减参数成像评估肝脂肪变性及其对心血管疾病风险的预测价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 770-777.
[2] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[3] 张凯, 乔永杰, 林志强, 刘健, 邓泽群, 谭飞, 曾健康, 李嘉欢, 李培杰, 周胜虎. 假体周围骨溶解中巨噬细胞极化的机制研究进展[J/OL]. 中华关节外科杂志(电子版), 2024, 18(05): 618-625.
[4] 戴睿, 张亮, 陈浏阳, 张永博, 吴丕根, 孙华, 杨盛, 孟博. 肠道菌群与椎间盘退行性变相关性的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 546-549.
[5] 李嘉兴, 孙乙文, 李文星. NLRP3炎性小体在急性胰腺炎中作用的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 300-304.
[6] 李玲, 刘亚, 李培玲, 张秀敏, 李萍. 直肠癌患者术后肠道菌群的变化与抑郁症相关性研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 607-610.
[7] 郭倩男, 史嘉玮, 董念国. T细胞不同代谢方式在移植排斥反应中的研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 315-320.
[8] 王雪玲, 曹欢, 顾劲扬. 肠道菌群在器官缺血再灌注损伤中的作用及机制研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(04): 247-250.
[9] 方道成, 唐春华, 胡媛媛. 肠道菌群对草酸钙肾结石形成的影响[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 509-513.
[10] 蔡艺丹, 方坚, 张志强, 陈莉, 张世安, 夏磊, 阮梅, 李东良. 经颈静脉肝内门体分流术对肝硬化门脉高压患者肠道菌群及肝功能的影响[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 285-293.
[11] 赵小民, 杨军, 田巍巍. 枳术颗粒联合利那洛肽治疗便秘型肠易激综合征的临床研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 465-469.
[12] 邱岭, 朱旭丽, 浦坚, 邢苗苗, 吴佳玲. 糖尿病肾病患者肠道菌群生态特点与胃肠道功能障碍的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 453-458.
[13] 宋燕秋, 戚桂艳, 杨双双, 周萍. 重症急性胰腺炎肠道菌群特征及早期肠内营养联合微生态制剂治疗的临床价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 442-447.
[14] 张杨杨, 项楚淇, 朱满生. 肌少性肥胖与非酒精性脂肪性肝病间的关系以及研究进展[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(04): 276-282.
[15] 曹亚丽, 高雨萌, 张英谦, 李博, 杜军保, 金红芳. 儿童坐位不耐受的临床进展[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 510-515.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?